soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 soul trial oral semaglutide cardiovascular

Sensitivity analyses using PRR, IC, and EBGM methodologies produced divergent results

Also, research has found that exercise will lead to better health outcomes, including improved blood glucose metrics

Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K et al

What is the recommended treatment approach for a patient with chronic Hepatitis B, fatty liver disease, and hypothyroidism on levothyroxine (thyroid hormone replacement) therapy, considering the use of injectable Glucagon-Like Peptide-1 (GLP-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic)?

Skin damage or lipodystrophy

Human Data: Mixed Early Signals Realworld analyses and observational studies have also hinted that people taking GLP1 drugs for diabetes or weight loss may have a lower risk of dementia, including Alzheimers, compared with users of other diabetes medicines